Takeda Pharmaceutical Company Limited (TAK)
| Previous close | 16.75 |
| Open | 16.87 |
| Bid | 16.65 x 1200 |
| Ask | 16.66 x 1400 |
| Day's range | 16.57 - 16.95 |
| 52-week range | 12.43 - 20.00 |
| Volume | 2,103,246 |
| Avg. volume | 3,510,170 |
| Market cap | 53.506B |
| Beta (5Y monthly) | 1.11 |
| PE ratio (TTM) | 20.56 |
| EPS (TTM) | 0.81 |
| Earnings date | N/A |
| Forward dividend & yield | 0.85 (5.07%) |
| Ex-dividend date | 29 Sep 2020 |
| 1y target est | 22.88 |
- Business Wire
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) ("Takeda") today announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited ("Teijin Pharma"), a Tokyo-based pharmaceutical company, for JPY 133.0 billion, subject to customary legal and regulatory closing conditions.
- Business Wire
BioLife Plasma Services Announces Expansion of Plasma Donation Centers Into California
BioLife Plasma Services announces expansion of plasma donation centers into California.
- Business Wire
Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate (TAK-919) in Japan.
